Day 1: Sunday, December 1, 2024
SESSION 1: Treatment advancements in people for people with HIV infections
Plenary Lecture
Part I: Update on the first human retrovirus, HTLV-1, the most oncogenic human virus
Part II: New therapeutic approach toward functional cure from studies of HIV pathogenesis
Robert Gallo, University of South Florida, Global Virus Network USA
Implementing LA agents for treatment and prevention. Challenges and opportunities
Carlos del Rio, Emory University, USA
Day 2: Monday, December 2, 2024
SESSION 2: Gertrude Elion Distinguished Lecturer Award session
My journey across HIV and emerging infections: Of viruses, people, science, bureaucracy, politics
Peter Piot, London School of Hygiene & Tropical Medicine, United Kingdom and Rega Institute, KU Leuven, Belgium
SESSION 3: mRNA and Antibodies for HIV prevention and cure strategies
Relevant concepts to engineer antibody-based molecules for HIV cure
Guido Ferrari, Duke University, USA
AAV-vectored delivery of HIV bnAbs for tackling pediatric HIV infection
Mauricio Martins, Scripps Research Institute, USA
Long-term continuous delivery of anti-HIV monoclonal antibodies using AAV vector
Ronald Desrosiers, University of Miami, USA
Oral Abstract Session I
James Termini, University of Miami, USA
Doubling dolutegravir dosage reduces the viral reservoir in ART-treated people with HIV
Alexander Pasternak, Amsterdam UMC, the Netherlands
Initiating opt-out HIV screening in metro atlanta pediatric emergency departments
Lauren Middlebrooks, Emory University, USA
Marie Lina Excellent, University of North Carolina at Chapel Hill, USA
SESSION 4: Industry Session
Gilead HIV clinical pipeline updates
Sean Collins, Gilead Sciences, USA
ViiV Healthcare pipeline update
Cindy Donovan, ViiV Healthcare, USA
Update on the MSD HIV pipeline: Prevention, treatment, and cure
Raphael Campo, MSD, USA
SESSION 5: NeuroAIDS
Plenary Lecture: HIV and the central nervous system: Biotypes and viral persistence
Avi Nath, National Institutes of Health, USA
HIV in the central nervous system; impact on HIV cure strategies
Monique Nijhuis, University Medical Center Utrecht, the Netherlands
Ongoing clinical trials to reverse NeuroAIDS
Scott Letendre, University of California at San Diego, USA
Oral Abstract Session II
Luis Romero Martin, Institut Paster, France
Vijayakumar Velu, Emory University, USA
Day 3: Tuesday, December 3, 2024
SESSION 6: Genetic and immunological approaches to HIV Cure
Plenary Lecture: Leveraging mRNA and lipid nanoparticle technology to develop a cure for HIV
Paula Cevaal, University of Melbourne, Australia
Understanding myeloid HIV infection as targets for virus eradication
Victor Garcia Martinez, University of Alabama Birmingham, USA
Oral Abstract Session III
Modeling the lung monocyte/macrophage reservoir in human TB
Collin Leese-Thompson, Emory University, USA
Kien Nguyen, Case Western Reserve University, USA
Alftan Dyson, ViiV Healthcare, USA
Summary of Posters and Meeting
Mario Stevenson, University of Miami, USA
Closing Remarks
Raymond F. Schinazi, Emory University, USA